Active Ingredient(s): Imipenem + Cilastatin +Relebactam
FDA Approved: * July 16, 2019
Pharm Company: * MERCK SHARP DOHME
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Recarbrio Overview

Imipenem/cilastatin/relebactam (Recarbrio) is a drug combination used as an antibiotic. In the United States it is approved for complicated urinary tract and complicated intra-abdominal infections.[1] See also Imipenem/cilastatin References ^ "FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections". Food and Drug Administration. July 17, cite.citation{font-style:inherit}.mw-parser-output .citation q{qu...

Read more Recarbrio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Recarbrio Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Imipenem + Cilastatin +Relebactam
  • Injection: 500mg + 500mg + 250mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (3 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 22 August 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA